



Stephen R. Cunningham, MD  
Chief Scientific Officer  
US Clinical Development

Novartis Pharmaceuticals Corporation  
One Health Plaza  
East Hanover, NJ 07936

Tel 862.778.4304  
Fax 973.515.0917  
Internet: stephen.cunningham@novartis.com

September 26, 2007

Dr. Joel Kupersmith  
Chief Research & Development Officer  
Office of Research and Development  
Department of Veterans Affairs  
810 Vermont Avenue, NW (12TT)  
Washington, DC 20420

RE: Master CRADA Template for VA and Novartis Pharmaceuticals Corp.

Dear Dr. Kupersmith:

On behalf of Novartis Pharmaceuticals Corp., I am pleased to provide you with this approval letter for the Final Master CRADA Template to be used for Novartis-sponsored Phase II/III, Phase III and Phase IV clinical drug trials conducted at VA centers nationwide. We hereby adopt the final version dated September 26, 2007 as the pre-negotiated template for General Medicines, as well as for Oncology.

This template will be distributed within Novartis upon notification that it has been released within the VA system.

Please impart our sincere thanks to all of your colleagues who worked so diligently to finalize this agreement. We look forward to collaborating with your centers on future research endeavors.

Sincerely,

Stephen Cunningham, MD  
Chief Scientific Officer  
U.S. Clinical Development

cc: John Hohneker, MD  
US Clinical Development & Med. Affairs  
Novartis Oncology Business Unit